SETTING: Kinshasa, Democratic Republic of Congo. OBJECTIVE: To identify programmatic interventions for improved survival in patients receiving treatment for tuberculosis (TB) at primary care clinics. DESIGN: Retrospective cohort of adult patients initiating anti-tuberculosis treatment between January 2006 and May 2007. RESULTS: Among 5685 patients, 390 deaths occurred during anti-tuberculosis treatment, of which half (52%) did so during the first 2 months. Patients with smear-negative pulmonary TB were at greater risk of death in the first 2 months of treatment (human immunodeficiency virus [HIV] positive HR 1.49, 95%CI 0.89-2.49; HIV-negative HR 1.77 95%CI 1.06-2.95), but not thereafter. Patients with extra-pulmonary TB were at increased risk of death in the first 2 months of anti-tuberculosis treatment if they were non-HIV-infected (HR 2.42, 95%CI 1.52-3.85), and were half as likely to die during the remainder of treatment (HIV-positive HR 0.46, 95%CI 0.22-0.97; HIV-negative HR 0.47, 95%CI 0.23-0.94). Antiretroviral therapy (ART) reduced the risk of death by an estimated 36% (HR 0.64, 95%CI 0.37-1.11). CONCLUSION: High mortality in the first months of anti-tuberculosis treatment could be reduced by addressing diagnostic delays, particularly for extra-pulmonary and smear-negative TB cases and, in HIV-infected patients, by initiation of ART soon after starting anti-tuberculosis treatment.
SETTING: Kinshasa, Democratic Republic of Congo. OBJECTIVE: To identify programmatic interventions for improved survival in patients receiving treatment for tuberculosis (TB) at primary care clinics. DESIGN: Retrospective cohort of adult patients initiating anti-tuberculosis treatment between January 2006 and May 2007. RESULTS: Among 5685 patients, 390 deaths occurred during anti-tuberculosis treatment, of which half (52%) did so during the first 2 months. Patients with smear-negative pulmonary TB were at greater risk of death in the first 2 months of treatment (human immunodeficiency virus [HIV] positive HR 1.49, 95%CI 0.89-2.49; HIV-negative HR 1.77 95%CI 1.06-2.95), but not thereafter. Patients with extra-pulmonary TB were at increased risk of death in the first 2 months of anti-tuberculosis treatment if they were non-HIV-infected (HR 2.42, 95%CI 1.52-3.85), and were half as likely to die during the remainder of treatment (HIV-positive HR 0.46, 95%CI 0.22-0.97; HIV-negative HR 0.47, 95%CI 0.23-0.94). Antiretroviral therapy (ART) reduced the risk of death by an estimated 36% (HR 0.64, 95%CI 0.37-1.11). CONCLUSION: High mortality in the first months of anti-tuberculosis treatment could be reduced by addressing diagnostic delays, particularly for extra-pulmonary and smear-negative TB cases and, in HIV-infectedpatients, by initiation of ART soon after starting anti-tuberculosis treatment.
Authors: S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch Journal: Infection Date: 2013-12-06 Impact factor: 3.553
Authors: M Sawadogo; F Ciza; S D Nzeyimana; A Shingiro; T Ndikumana; T Demeulenaere; M Khogali; M Edginton; A J Reid; A M V Kumar; A D Harries Journal: Public Health Action Date: 2015-11-12
Authors: Bruce J Kirenga; Jonathan Levin; Irene Ayakaka; William Worodria; Nancy Reilly; Francis Mumbowa; Helen Nabanjja; Grace Nyakoojo; Kevin Fennelly; Susan Nakubulwa; Moses Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Roy D Mugerwa; Peter G Smith; Jerrold J Ellner; Edward C Jones-López Journal: PLoS One Date: 2014-03-07 Impact factor: 3.240
Authors: Lydia Nakiyingi; Bareng A S Nonyane; Willy Ssengooba; Bruce J Kirenga; Damalie Nakanjako; Gloria Lubega; Pauline Byakika-Kibwika; Moses L Joloba; Jerry J Ellner; Susan E Dorman; Harriet Mayanja-Kizza; Yukari C Manabe Journal: PLoS One Date: 2015-07-29 Impact factor: 3.240
Authors: Elizabeth A Reddy; Boniface N Njau; Susan C Morpeth; Kathryn E Lancaster; Alison C Tribble; Venance P Maro; Levina J Msuya; Anne B Morrissey; Gibson S Kibiki; Nathan M Thielman; Coleen K Cunningham; Werner Schimana; John F Shao; Shein-Chung Chow; Jason E Stout; John A Crump; John A Bartlett; Carol D Hamilton Journal: BMC Infect Dis Date: 2014-02-20 Impact factor: 3.090
Authors: Anna Odone; Silvia Amadasi; Richard G White; Theodore Cohen; Alison D Grant; Rein M G J Houben Journal: PLoS One Date: 2014-11-12 Impact factor: 3.240